Warning: The NCBI web site requires JavaScript to function. more...
Gout. Novel therapies for treatment of gout and hyperuricemia.
Terkeltaub R.
Arthritis Res Ther. 2009;11(4):236. Epub 2009 Jul 23. Review.
Related citations
Update on gout: new therapeutic strategies and options.
Nat Rev Rheumatol. 2010 Jan;6(1):30-8. Review.
Gout and hyperuricemia.
Chilappa CS, Aronow WS, Shapiro D, Sperber K, Patel U, Ash JY.
Compr Ther. 2010;36:3-13. Review.
[Gout and comorbidities associated with hyperuricemia].
Majdan M, Borys O.
Ann Acad Med Stetin. 2010;56 Suppl 1:34-9. Review. Polish.
A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout.
Chao J, Terkeltaub R.
Curr Rheumatol Rep. 2009 Apr;11(2):135-40. Review.
Febuxostat: a new agent for lowering serum urate.
Keenan RT, Pillinger MH.
Drugs Today (Barc). 2009 Apr;45(4):247-60. Review.
Overview of hyperuricaemia and gout.
Masseoud D, Rott K, Liu-Bryan R, Agudelo C.
Curr Pharm Des. 2005;11(32):4117-24. Review.
Advances in the management of gout and hyperuricaemia.
Hoskison TK, Wortmann RL.
Scand J Rheumatol. 2006 Jul-Aug;35(4):251-60. Review.
Difficult-to-treat gouty arthritis: a disease warranting better management.
Schlesinger N.
Drugs. 2011 Jul 30;71(11):1413-39. doi: 10.2165/11592290-000000000-00000. Review.
Developments in the scientific and clinical understanding of gout.
So A.
Arthritis Res Ther. 2008;10(5):221. Epub 2008 Oct 10. Review.
Crystal ball gazing: new therapeutic targets for hyperuricaemia and gout.
Dalbeth N, Merriman T.
Rheumatology (Oxford). 2009 Mar;48(3):222-6. Epub 2008 Dec 24. Review.
A literature review of the epidemiology and treatment of acute gout.
Kim KY, Ralph Schumacher H, Hunsche E, Wertheimer AI, Kong SX.
Clin Ther. 2003 Jun;25(6):1593-617. Review.
Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.
Bomalaski JS, Clark MA.
Curr Rheumatol Rep. 2004 Jun;6(3):240-7. Review.
New agents for the treatment of gout and hyperuricemia: febuxostat, puricase, and beyond.
Curr Rheumatol Rep. 2010 Apr;12(2):130-4. Review.
PEG-uricase in the management of treatment-resistant gout and hyperuricemia.
Sherman MR, Saifer MG, Perez-Ruiz F.
Adv Drug Deliv Rev. 2008 Jan 3;60(1):59-68. Epub 2007 Aug 14. Review.
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N.
Arthritis Rheum. 2008 Nov 15;59(11):1540-8.
Purine metabolism and hyperuricemic states. 'The point of view of the rheumatologist'.
Peronato G.
Contrib Nephrol. 2005;147:1-21. Review.
New developments in clinically relevant mechanisms and treatment of hyperuricemia.
Lee SJ, Terkeltaub RA.
Curr Rheumatol Rep. 2006 Jun;8(3):224-30. Review.
Pathophysiology, clinical presentation and treatment of gout.
Teng GG, Nair R, Saag KG.
Drugs. 2006;66(12):1547-63. Review.
[Therapy of hyperuricemia and gout].
Pöllmann G, Kullich W, Klein G.
Wien Med Wochenschr. 1997;147(16):382-7. Review. German.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on